Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The shares of Novavax, Inc. (NASDAQ:NVAX) are surging in pre-market trading, up 9% at $205.78, after the drugmaker announced its coronavirus vaccine was highly effective against both the original and U.K. variant strains of the virus.

Novavax Stock Reclaims $200 Level After Vaccine Update

Novavax stock rocketed Friday after the company said final-phase testing showed its coronavirus vaccine proved to be 96.4% effective against the original viral strain that causes Covid-19. The post Novavax Stock Rockets After Covid Vaccine Proves 96.4% Effective In Testing appeared first on Investor's Business Daily.

Novavax Stock Rockets After Covid Vaccine Proves 96.4% Effective In Testing

AMC Entertainment

Palantir Technologies

One of the most common questions traders have about stocks is “Why Is It Moving?” That's why Benzinga created the Why Is It Moving, or WIIM, feature in Benzinga Pro.

Is Now The Time To Buy Stock In Novavax, Palantir, AMC Or Facebook?

Novavax's COVID-19 vaccine was 89.7% effective at preventing COVID-19 with symptoms in a trial of more than 15,000 people, the US biotech announced Thursday. The shot held up against the highly contagious coronavirus variant circulating in the UK and the US, called B.1.1.7, Novavax said. The vaccine worked 86.3% of the time against this particular variant, Novavax said in a press release.

Novavax's COVID-19 vaccine was 89.7% effective in a large trial, and worked against the contagious virus variant first found in the UK

It's possible. Whether it's probable, though, is a different story.

Could Novavax Win U.S. Authorization for Its COVID Vaccine by May?

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by over 20% pre-market. This is why it happened.

NVAX Stock Price Increases Over 20% Pre-Market: Why It Happened

Moderna

Their stock market success stories are far from over.

2 Vaccine Stocks That Could Double Your Money

Co-Diagnostics

Fulgent Genetics

Johnson & Johnson

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Biotech Stocks: What Will 2021 Look Like?

The efficacy was far lower against the South African variant, though.

Novavax Coronavirus Vaccine Candidate Shows 96% Efficacy With Original Strain, 86% Against U.K. Variant

Novavax, Inc (NASDAQ: NVAX) shares spiked nearly 32% in the after-hours and regular session on Thursday. What Happened: The Maryland-based biotechnology company said Thursday that its COVID-19 vaccine, NVX-CoV2373, was 96.4% effective “against mild, moderate and severe disease caused by the original COVID-19 strain” in Phase 3 trials.

Why Novavax Shares Spiked 32% Today

Novavax Inc. NVAX shares rallied in the extended session Thursday after the biotech drug maker said studies show its COVID-19 vaccine is highly effective. Novavax shares surged 17% after hours, following an 8.8% gain to close the regular session at $187.63.

Novavax stock rallies on COVID-19 vaccine study results

- 100% protection against severe disease - Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 - Efficacy against variants confirmed in U.K. and South Africa GAITHERSBURG, Md., March 11, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the company's vaccine candidate.

Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials

GameStop

The recent mega-cap stocks sell-off was bizarre and painful to Nasdaq stocks. But it is already paying rewards to those who stepped up.

These 3 Mega-Cap Stocks Got Too Cheap for No Good Reason

It's shifting from an unprofitable biotech to a company collecting billions in revenue.

What Are Novavax's Long-Term Prospects?

NVAX's quarterly revenue rose over 75% Q/Q. COVID-19 supply spurred growth. Regulatory approval for a vaccine may not happen until Q2. It could take a few more months to build out manufacturing capabilities.

Novavax: Uncertain COVID-19 Vaccine Approval Triggers Violent Sell-Off

Datadog

Plug Power

Zoom Video

Wall Street professionals are counting on these popular growth stocks to bounce back.

4 Beaten-Down Nasdaq Stocks With 57% to 78% Upside, According to Wall Street

This biotech stock looks like a better buy now than it did a few weeks ago.

3 Reasons to Buy Novavax Stock After Its Huge Pullback

AbbVie

Bristol-Myers

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

There isn't much juice left in this coronavirus vaccine drugmaker's stock.

Could Novavax Be a Millionaire-Maker Stock?

This Warning From the CEO of the World's Biggest Vaccine Maker Could Be Bad News for Novavax

Here's Why the Novavax CEO is Shrugging Off Moderna's and Pfizer's Market Dominance

GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.

Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat

Pfizer

AstraZeneca

BioNTech SE

CureVac B.V

Sinovac Biotech

The companies in line for the biggest gains – and the shareholders who have already made fortunes

From Pfizer to Moderna: who's making billions from Covid-19 vaccines?

Ocugen, Inc.

Vaxart

And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.

This Is the Cheapest Coronavirus Vaccine Stock Right Now

Novavax stock (NASDAQ: NVAX) dropped 15% over the last five trading days and has underperformed the S&P 500 which remained almost flat over the same period. The stock is also down by almost 22% over the last ten trading days.

News for Novavax Stock (NVAX)